M-Brain Appoints New CEO
M-Brain, a global leader in market and media intelligence solutions, has appointed Christian Cedercreutz Chief Executive Officer as of 13.8.2018.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180524005676/en/
M-Brain, a global leader in market and media intelligence solutions, has appointed Christian Cedercreutz Chief Executive Officer as of 13.8.2018. (Photo: Business Wire)
Christian holds a Master of Economics degree from Hanken School of Economics in Helsinki. His career has been built with IBM over the past 20 years, in which he has held various management positions in five different European countries. Christian brings strong consultative selling experience and has over the years worked across the IBM Corporation in roles such as leading global client relationships, and leading SW and HW technology businesses in Finland. His most recent role has been to lead the cognitive SW solutions (Watson) business in Finland.
Simultaneously the company’s long-time CEO and Chairman of the Board Kim Nyberg will step down from his position as CEO. He and Marjukka Nyberg, the founder of M-Brain, will retire from the company by the end of the year. They will continue as members of the board of M-Brain.
“I’m really excited to join the M-Brain team. I’m convinced that we can continue to enhance the value we bring to our clients globally and also develop new services and solutions that cater to the future demands of our customers. M-Brain offers a good foundation to build upon, with talented people, smart technology platforms and excellent industry and customer understanding”, says Christian Cedercreutz.
“After a long career in PR & Communications during the industry’s upswing, I have truly enjoyed having the opportunity to be part of building yet another prominent industry, the Business and Market Intelligence”, says Kim Nyberg. “As the industry is moving more and more towards complex AI based solutions, it was vital for us to find somebody whose expertise included this particular knowledge. At the same time, our challenge is to continue expanding globally. Christian’s strong international sales experience is therefore highly appreciated.”
M-Brain offers best-in-class intelligence services and software through a workforce of 400 global experts. The company delivers value to its customers through a combination of industry best-practice expertise and in-house proprietary artificial intelligence development. Operating from 13 countries across the globe M-Brain supports its customers operations with optimized intelligence solutions, enabling them to seize opportunities, mitigate risks and make strategic business decisions based on objective insight.
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ADVA unveils commercially ready disaggregated cell site gateway solution at TIP ’1913.11.2019 12:15:00 CET | Press release
ADVA (FSE: ADV) today announced the commercial readiness of its disaggregated cell site gateway (DCSG) solution at the Telecom Infra Project (TIP) Summit. Powered by ADVA’s Ensemble Activator network operating system (NOS), the integrated white box solution comes with a comprehensive bundle of installation, commissioning and monitoring services for rapid network deployment. The technology is currently on display in a 5G demo at the TIP Summit with ADVA’s software running on Edgecore’s new family of DCSG devices. The showcase highlights how mobile network operators (MNOs) now have an easy and cost-effective route to mass small cell deployment for 5G services. Already successful in a series of trials in global MNO networks, Ensemble Activator is the industry’s only true carrier-grade NOS for bare-metal switches. “This is a landmark moment for mobile networks. Now that MNOs can leverage our DCSG solution as a simple and complete answer for evolving their infrastructure to 5G, the shackles
Visa Introduces Team Visa Roster Ahead of the Olympic and Paralympic Games Tokyo 202013.11.2019 12:00:00 CET | Press release
Visa (NYSE: V), the Worldwide Payment Technology Partner of the Olympic and Paralympic Games, today announced its most diverse roster of athletes on Team Visa Tokyo 2020. Representing 43 countries, the most in Team Visa history, the current roster is comprised of 70+ athletes across 30+ sports, including new additions to The Games: Surfing, Skateboarding and Sport Climbing. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191113005219/en/ Visa Introduces Team Visa Roster Ahead of the Olympic and Paralympic Games Tokyo 2020 (Graphic: Business Wire) The announcement was made at the Team Visa Summit, hosted at the company’s San Francisco Innovation Center. The Summit offers athletes resources on how to improve financial literacy, benefit from digital payments and elevate their personal brand. “As one of the longest standing partners of the Olympic and Paralympic Games, Visa looks forward to Tokyo 2020. Set to be the largest Games
Vertex Confirms Wales Offer Accepted for Access to All Licensed Cystic Fibrosis Medicines13.11.2019 11:29:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today confirms that NHS Wales has accepted an offer for all currently licensed Vertex cystic fibrosis (CF) medicines and any future indications of these medicines under the same terms as the recently announced agreement with NHS England. This means that once the contract is finalized, patients with CF in Wales ages 2 years and older who have two copies of the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene can access ORKAMBI ® (lumacaftor/ivacaftor) and CF patients ages 12 years and older who either have two copies of the F508del mutation or one copy of the F508del mutation and a copy of one of the other 14 licensed mutations can access SYMKEVI® (tezacaftor/ivacaftor) in combination with ivacaftor in the coming weeks. The agreement also offers expanded access to KALYDECO ® (ivacaftor) to include those patients ages 12 months and older who have one of the nine licensed gating mutations. “Today’s a
Software Testing and Digital Transformation Partners Recognized at 2019 Tricentis Partner Awards13.11.2019 11:00:00 CET | Press release
Tricentis, the cloud’s #1 Continuous Testing Platform, today recognized top-performing partners from around the world during Tricentis Accelerate 2019 in Vienna, Austria. In its 5th year, the Tricentis Partner Awards recognize organizations for accelerating digital transformation across the enterprise. Award winners were selected from more than 300 different partners worldwide based on their collaboration with Tricentis, customers, and their advocacy for Tricentis’ automation methodologies. “Tricentis partners are leading the way for organizations to innovate faster, reduce business risk, and optimize cost,” said Alan Ota, Senior Vice President of Strategic Alliances, Tricentis. “Our partners are instrumental to our business and are focused on delivering the best in-class testing solutions to our joint customers. Our tremendous growth would not be possible without our global partners. We’re proud to acknowledge the achievements made by our partners in 2019 and look forward to continuin
Applicaster Appoints Jason Johns as Vice President of Sales, EMEA and APAC13.11.2019 10:00:00 CET | Press release
Applicaster, the company simplifying the lifecycle management of direct-to-consumer media applications, today announced the appointment of Jason Johns as Vice President of Sales, EMEA and APAC. In his role, Johns will oversee Applicaster’s EMEA and APAC commercial and go-to-market strategies. “There is an incredible amount of opportunity in the media app market,” said Johns. “Because of our ability to enable frictionless growth for customers, we’re very well positioned to take advantage of this opportunity. Beyond the market opportunity, I was attracted to Applicaster because of the company’s customer-first culture plus its ability and desire to drive value lead engagements. Few businesses buy technology without a clear understanding of the business case and full transparency of the cost-of-ownership around their technology investments - Applicaster understands this and provides flexible commercial models that scale and can easily be upgraded and expanded as business requirements evolv
Clovis Oncology Announces Reimbursement for Rubraca® (rucaparib) Tablets for Women with Relapsed Ovarian Cancer in Italy13.11.2019 09:00:00 CET | Press release
Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the Italian Medicines Agency (AIFA) has approved rucaparib for reimbursement in Italy. Rucaparib will soon be available as an option for monotherapy maintenance treatment for adults with relapsed, platinum-sensitive high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer that has responded to platinum-based chemotherapy.3 Rucaparib is indicated for eligible patients regardless of BRCA status, which means it can be prescribed for women who harbor a BRCA mutation or who are BRCA wild-type.3 “We very much welcome the arrival of the PARP inhibitor rucaparib, which offers a new treatment option after surgery and two lines of chemotherapy to all eligible women affected by relapsed ovarian cancer,” declared Nicoletta Cerana, National President of Acto Onlus, the number one Italian network of patient associations involved in the fight against ovarian cancer and gynecological tumors. “Ovarian cancer is a highly lethal